Enhabit, Inc. (NYSE:EHAB) Stock Position Trimmed by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. cut its position in Enhabit, Inc. (NYSE:EHAB) by 27.7% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 621,569 shares of the company’s stock after selling 238,407 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.24% of Enhabit worth $4,910,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EHAB. Gladius Capital Management LP bought a new stake in shares of Enhabit during the 2nd quarter worth about $31,000. Quarry LP raised its holdings in shares of Enhabit by 242.2% in the 2nd quarter. Quarry LP now owns 3,703 shares of the company’s stock worth $33,000 after purchasing an additional 2,621 shares in the last quarter. Stoneridge Investment Partners LLC purchased a new position in shares of Enhabit in the third quarter worth approximately $81,000. Canada Pension Plan Investment Board purchased a new position in shares of Enhabit in the second quarter worth approximately $93,000. Finally, AQR Capital Management LLC purchased a new position in Enhabit during the second quarter valued at approximately $94,000.

Enhabit Price Performance

Shares of NYSE:EHAB opened at $8.52 on Friday. Enhabit, Inc. has a 12 month low of $6.85 and a 12 month high of $11.74. The company’s 50-day moving average price is $7.56 and its two-hundred day moving average price is $8.31. The company has a quick ratio of 1.46, a current ratio of 1.46 and a debt-to-equity ratio of 0.85. The firm has a market cap of $428.39 million, a P/E ratio of -3.67 and a beta of 1.89.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $253.60 million during the quarter, compared to analyst estimates of $261.69 million. Enhabit had a negative net margin of 11.24% and a positive return on equity of 1.67%. During the same quarter in the prior year, the business earned $0.03 earnings per share. As a group, research analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Leerink Partners reiterated a “market perform” rating and issued a $8.00 target price (down from $8.50) on shares of Enhabit in a research note on Tuesday, November 19th. Jefferies Financial Group upgraded shares of Enhabit from a “hold” rating to a “buy” rating and upped their target price for the company from $8.25 to $9.50 in a research note on Monday, December 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $8.75.

Insider Transactions at Enhabit

In related news, Director Stuart M. Mcguigan acquired 15,000 shares of Enhabit stock in a transaction on Tuesday, December 10th. The stock was purchased at an average cost of $8.81 per share, with a total value of $132,150.00. Following the completion of the transaction, the director now directly owns 46,810 shares in the company, valued at $412,396.10. This trade represents a 47.15 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bolton bought 4,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were purchased at an average cost of $8.69 per share, with a total value of $34,760.00. Following the acquisition, the director now directly owns 98,144 shares of the company’s stock, valued at approximately $852,871.36. This represents a 4.25 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.90% of the company’s stock.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.